JP6131046B2 - 抗癌剤により誘発される末梢神経障害を抑制する化合物 - Google Patents

抗癌剤により誘発される末梢神経障害を抑制する化合物 Download PDF

Info

Publication number
JP6131046B2
JP6131046B2 JP2012533416A JP2012533416A JP6131046B2 JP 6131046 B2 JP6131046 B2 JP 6131046B2 JP 2012533416 A JP2012533416 A JP 2012533416A JP 2012533416 A JP2012533416 A JP 2012533416A JP 6131046 B2 JP6131046 B2 JP 6131046B2
Authority
JP
Japan
Prior art keywords
compound
ethyl
carboxylate
acid
sulfamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012533416A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518032A (ja
JP2013518032A5 (cg-RX-API-DMAC7.html
Inventor
直美 北本
直美 北本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43770309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6131046(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to JP2012533416A priority Critical patent/JP6131046B2/ja
Publication of JP2013518032A publication Critical patent/JP2013518032A/ja
Publication of JP2013518032A5 publication Critical patent/JP2013518032A5/ja
Application granted granted Critical
Publication of JP6131046B2 publication Critical patent/JP6131046B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2012533416A 2010-01-27 2011-01-26 抗癌剤により誘発される末梢神経障害を抑制する化合物 Active JP6131046B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012533416A JP6131046B2 (ja) 2010-01-27 2011-01-26 抗癌剤により誘発される末梢神経障害を抑制する化合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010015935 2010-01-27
JP2010015935 2010-01-27
JP2012533416A JP6131046B2 (ja) 2010-01-27 2011-01-26 抗癌剤により誘発される末梢神経障害を抑制する化合物
PCT/JP2011/052077 WO2011093512A1 (en) 2010-01-27 2011-01-26 Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016056186A Division JP2016175903A (ja) 2010-01-27 2016-03-18 抗癌剤により誘発される末梢神経障害を抑制する化合物

Publications (3)

Publication Number Publication Date
JP2013518032A JP2013518032A (ja) 2013-05-20
JP2013518032A5 JP2013518032A5 (cg-RX-API-DMAC7.html) 2014-02-13
JP6131046B2 true JP6131046B2 (ja) 2017-05-17

Family

ID=43770309

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012533416A Active JP6131046B2 (ja) 2010-01-27 2011-01-26 抗癌剤により誘発される末梢神経障害を抑制する化合物
JP2016056186A Pending JP2016175903A (ja) 2010-01-27 2016-03-18 抗癌剤により誘発される末梢神経障害を抑制する化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016056186A Pending JP2016175903A (ja) 2010-01-27 2016-03-18 抗癌剤により誘発される末梢神経障害を抑制する化合物

Country Status (41)

Country Link
US (5) US20130046000A1 (cg-RX-API-DMAC7.html)
EP (1) EP2528598B1 (cg-RX-API-DMAC7.html)
JP (2) JP6131046B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120118044A (cg-RX-API-DMAC7.html)
CN (2) CN102821763B (cg-RX-API-DMAC7.html)
AR (1) AR080024A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011211294B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012018434A2 (cg-RX-API-DMAC7.html)
CA (1) CA2788150C (cg-RX-API-DMAC7.html)
CL (1) CL2012002079A1 (cg-RX-API-DMAC7.html)
CO (1) CO6592110A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120412A (cg-RX-API-DMAC7.html)
CY (1) CY1117268T1 (cg-RX-API-DMAC7.html)
DK (1) DK2528598T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2012000209A (cg-RX-API-DMAC7.html)
EA (1) EA201290697A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12012126A (cg-RX-API-DMAC7.html)
ES (1) ES2560215T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20166441B (cg-RX-API-DMAC7.html)
HR (1) HRP20160165T1 (cg-RX-API-DMAC7.html)
HU (1) HUE027310T2 (cg-RX-API-DMAC7.html)
IL (1) IL221066A (cg-RX-API-DMAC7.html)
MA (1) MA34014B1 (cg-RX-API-DMAC7.html)
ME (1) ME02364B (cg-RX-API-DMAC7.html)
MX (1) MX2012008514A (cg-RX-API-DMAC7.html)
MY (1) MY163936A (cg-RX-API-DMAC7.html)
NZ (1) NZ601635A (cg-RX-API-DMAC7.html)
PE (1) PE20121694A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012501538A1 (cg-RX-API-DMAC7.html)
PL (1) PL2528598T3 (cg-RX-API-DMAC7.html)
PT (1) PT2528598E (cg-RX-API-DMAC7.html)
RS (1) RS54591B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201503402XA (cg-RX-API-DMAC7.html)
SI (1) SI2528598T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600103B (cg-RX-API-DMAC7.html)
TN (1) TN2012000364A1 (cg-RX-API-DMAC7.html)
TW (1) TWI481401B (cg-RX-API-DMAC7.html)
UA (1) UA109540C2 (cg-RX-API-DMAC7.html)
UY (1) UY33203A (cg-RX-API-DMAC7.html)
WO (1) WO2011093512A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201205681B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428477B2 (en) * 2012-04-27 2016-08-30 Nippon Zoki Pharmaceutical Co., Ltd. Trans-2-decenoic acid derivative and drug containing same
CN105934253A (zh) * 2013-12-17 2016-09-07 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法
JP6718884B2 (ja) 2015-05-08 2020-07-08 武田薬品工業株式会社 環状化合物
KR102689256B1 (ko) 2015-06-17 2024-07-30 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
RU2742337C2 (ru) * 2016-09-09 2021-02-04 Такеда Фармасьютикал Компани Лимитед Циклическое соединение
WO2019047812A1 (zh) * 2017-09-07 2019-03-14 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804374A (en) 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
EP0252146B1 (en) 1986-01-09 1994-05-25 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
WO1988005083A1 (en) 1986-12-24 1988-07-14 Whitehead Institute For Biomedical Research Method of inducible gene expression
WO1989007614A1 (en) 1988-02-12 1989-08-24 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
EP0407411B1 (en) 1988-03-01 1993-11-10 Whitehead Institute For Biomedical Research ACTIVITION OF NF-kB PRECURSOR
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
EP0465565B1 (en) 1989-03-31 1996-05-15 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5158883A (en) 1989-09-13 1992-10-27 Cornell Research Foundation, Inc. Method of using aminoarginine to block nitric oxide formation in vitro
US5059712A (en) 1989-09-13 1991-10-22 Cornell Research Foundation, Inc. Isolating aminoarginine and use to block nitric oxide formation in body
WO1992003137A1 (en) 1990-08-23 1992-03-05 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
WO1992017168A1 (en) 1991-04-04 1992-10-15 The Children's Medical Center Corporation Method of preventing nmda receptor-mediated neuronal damage
US5455279A (en) 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
ATE182076T1 (de) 1991-04-19 1999-07-15 Childrens Medical Center Verfahren zur vorbeugung nmda-rezeptorkomplex- vermittelter neuronaler schäden
US6071876A (en) 1991-04-19 2000-06-06 Children's Medical Center Corporation Method of preventing NMDA receptor complex-mediated neuronal damage
MX9709442A (es) * 1995-06-07 1998-02-28 Sugen Inc Metodo y composiciones para la inhibicion de interacciones entre proteina adaptadora y tirosinquinasa.
US20020052019A1 (en) 1997-11-13 2002-05-02 Genentech Inc Human toll homologue
US20030032090A1 (en) 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
ATE381574T1 (de) 1997-10-17 2008-01-15 Genentech Inc Menschliche toll-homologe
ZA989147B (en) 1997-10-17 2000-04-07 Genentech Inc Human toll homologues.
US20080275104A1 (en) 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US20040072138A1 (en) 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
AU1539399A (en) 1997-11-25 1999-06-15 Medical University Of South Carolina Inhibitors of nitric oxide synthase
EP1063228B1 (en) 1998-03-09 2005-01-19 Takeda Pharmaceutical Company Limited Cycloalkene derivatives, process for producing the same, and use
DE60045033D1 (de) 1999-08-06 2010-11-11 Takeda Pharmaceutical Substituierte aromatische ringverbindungen, verfahren zu ihrer herstellung und ihre anwendung
SE9903930D0 (sv) * 1999-10-29 1999-10-29 Astra Pharma Inc Novel compounds and a novel process for their preparation
CN1416341B (zh) 2000-02-04 2010-05-05 武田药品工业株式会社 稳定的乳液组合物
AU6488901A (en) 2000-05-25 2001-12-03 Schering Corp Human receptor proteins; related reagents and methods
CA2685447C (en) 2000-08-10 2013-05-28 Takeda Pharmaceutical Company Limited Pharmaceutical composition
DE60144570D1 (de) 2000-10-18 2011-06-16 Takeda Pharmaceutical Verfahren zur herstellung von optisch aktiven sulfonamiden und zwischenprodukte zur deren synthese
JP4498678B2 (ja) 2000-11-30 2010-07-07 株式会社トクヤマ 基板およびその製造方法
AU2002221099A1 (en) 2000-12-08 2002-06-18 Takeda Chemical Industries Ltd. Combination drugs
JP5137289B2 (ja) 2001-08-03 2013-02-06 武田薬品工業株式会社 安定な乳化組成物
WO2003084527A1 (en) 2002-04-08 2003-10-16 Takeda Chemical Industries, Ltd. Severe sepsis preventive therapeutic agent
US8710095B2 (en) 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
WO2004074435A2 (en) 2003-01-30 2004-09-02 Emory University Methods for identifying and administering agents that bias the immune response via dendritic cells
WO2004075865A2 (en) 2003-02-27 2004-09-10 3M Innovative Properties Company Selective modulation of tlr-mediated biological activity
JP2006523452A (ja) 2003-03-25 2006-10-19 スリーエム イノベイティブ プロパティズ カンパニー 共通のＴｏｌｌ様受容体を通じて媒介される細胞活性の選択的活性化
JP2007505629A (ja) 2003-09-17 2007-03-15 スリーエム イノベイティブ プロパティズ カンパニー Ｔｌｒ遺伝子発現の選択的調節
US8034619B2 (en) 2003-12-19 2011-10-11 University Of Cincinnati Polyamides for nucleic acid delivery
TWI462745B (zh) 2005-04-28 2014-12-01 Takeda Pharmaceutical 安定的乳化組成物
BRPI0611079A2 (pt) 2005-06-03 2010-08-03 Ono Pharmaceutical Co agentes para a regeneração e/ou proteção de nervos
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
US20090175835A1 (en) 2006-02-07 2009-07-09 Korea Institute Of Radiological & Medical Sciences Composition for treating damage of central or peripheral nerve system
US7985538B2 (en) 2006-02-23 2011-07-26 Yale University Drug resistance and methods of reversing
US7943588B2 (en) 2006-03-28 2011-05-17 Trustees Of Dartmouth College Method for preventing or treating neuropathic pain
WO2007114296A1 (ja) 2006-03-30 2007-10-11 Hiroshima University スクリーニング方法
WO2007123186A1 (ja) * 2006-04-20 2007-11-01 Takeda Pharmaceutical Company Limited 医薬
JPWO2007132825A1 (ja) 2006-05-15 2009-09-24 武田薬品工業株式会社 医薬
US20090209585A1 (en) 2006-07-07 2009-08-20 Takashi Ichikawa Cycloalkene derivatives, process for production of the derivatives, and use of the same
EP1882687A1 (en) * 2006-07-27 2008-01-30 Amorepacific Corporation Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
WO2008112887A1 (en) 2007-03-13 2008-09-18 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US8399421B2 (en) 2007-03-30 2013-03-19 The Board Of Regents Of The University Of Texas System Treatment for neuropathic pain due to spinal cord injury
WO2009059050A2 (en) 2007-10-30 2009-05-07 The Regents Of The University Of Colorado Tlr modulators and methods for using the same
WO2009145814A2 (en) 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
JP5238381B2 (ja) 2008-07-07 2013-07-17 スタンレー電気株式会社 照明用車両用灯具
CA2774008C (en) 2009-09-23 2017-06-20 The Regents Of The University Of Colorado, A Body Corporate Toll-like receptor modulators and uses thereof

Also Published As

Publication number Publication date
TN2012000364A1 (en) 2014-01-30
KR20120118044A (ko) 2012-10-25
ME02364B (me) 2016-06-20
AR080024A1 (es) 2012-03-07
ECSP12012126A (es) 2012-09-28
ES2560215T3 (es) 2016-02-17
GEP20166441B (en) 2016-03-10
SMT201600103B (it) 2016-04-29
CL2012002079A1 (es) 2012-12-21
CR20120412A (es) 2012-11-13
UA109540C2 (uk) 2015-09-10
JP2016175903A (ja) 2016-10-06
WO2011093512A1 (en) 2011-08-04
US20160166526A1 (en) 2016-06-16
DK2528598T3 (en) 2016-03-07
PT2528598E (pt) 2016-03-04
BR112012018434A2 (pt) 2016-04-19
SI2528598T1 (sl) 2016-04-29
CN102821763B (zh) 2017-09-22
US20150203464A1 (en) 2015-07-23
CO6592110A2 (es) 2013-01-02
JP2013518032A (ja) 2013-05-20
AU2011211294A1 (en) 2012-09-20
RS54591B1 (sr) 2016-08-31
TW201130482A (en) 2011-09-16
EP2528598B1 (en) 2016-01-13
MY163936A (en) 2017-11-15
EP2528598A1 (en) 2012-12-05
AU2011211294B2 (en) 2014-11-13
CN104744321A (zh) 2015-07-01
US8901171B2 (en) 2014-12-02
SG182522A1 (en) 2012-08-30
CA2788150A1 (en) 2011-08-04
SG10201503402XA (en) 2015-06-29
US20130046000A1 (en) 2013-02-21
PL2528598T3 (pl) 2016-06-30
US20150051256A1 (en) 2015-02-19
TWI481401B (zh) 2015-04-21
US20130345304A1 (en) 2013-12-26
PE20121694A1 (es) 2012-12-06
MA34014B1 (fr) 2013-02-01
IL221066A (en) 2016-10-31
UY33203A (es) 2011-08-31
HUE027310T2 (en) 2016-10-28
CA2788150C (en) 2017-06-06
HRP20160165T1 (hr) 2016-03-11
CN102821763A (zh) 2012-12-12
PH12012501538A1 (en) 2015-11-09
CY1117268T1 (el) 2017-04-26
NZ601635A (en) 2013-06-28
AU2011211294A2 (en) 2012-10-04
HK1177423A1 (zh) 2013-08-23
EA201290697A1 (ru) 2013-02-28
ZA201205681B (en) 2013-09-25
DOP2012000209A (es) 2012-12-31
MX2012008514A (es) 2012-08-17

Similar Documents

Publication Publication Date Title
JP2016175903A (ja) 抗癌剤により誘発される末梢神経障害を抑制する化合物
KR20030016224A (ko) 안정한 에멀젼 조성물
KR20070009746A (ko) 통증의 치료에 사용하기 위한 알파-2-델타 리간드와ｐｄｅｖ 억제제의 상승작용 조합물
US12144815B2 (en) Use of aprepitant for treating Alzheimer's disease
JPWO2007132825A1 (ja) 医薬
JP2024096817A (ja) インドール化合物を用いた疼痛又は間質性膀胱炎の治療方法
KR101321633B1 (ko) 안정한 유화 조성물
US20090312311A1 (en) Combination of organic compounds
JP2022503784A (ja) てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用
RU2791025C2 (ru) Способ лечения боли или интерстициального цистита с использованием индольного соединения
HK1177423B (en) Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent
RU2776845C2 (ru) Аналоги целастрола
HK40049577B (en) Indole compound for treating interstitial cystitis
HK40049577A (en) Indole compound for treating interstitial cystitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150728

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170417

R150 Certificate of patent or registration of utility model

Ref document number: 6131046

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250